Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (NASDAQ: EOLS) has appointed Brady Stewart, a digital and beauty innovator, to its Board of Directors, enhancing its leadership team. Stewart brings over 20 years of experience in digital innovation and direct-to-consumer strategies, currently serving as Chief Commercial Officer at Forma Brands. The Chairman, Vikram Malik, emphasized her potential contribution as the company aims to be a leading multi-product aesthetics company. Stewart expressed her excitement to join at a pivotal moment, highlighting the potential of the company's product, Jeuveau®, in transforming the aesthetic neurotoxin industry.
Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.
Evolus, Inc. (NASDAQ: EOLS) has been added to the Nasdaq Biotechnology Index (NBI) as part of its annual reconstitution. This inclusion is expected to enhance Evolus' visibility and shareholder base. CFO Lauren Silvernail indicated that robust sales and market share gains position the company for a strong finish in 2021 and growth in 2022. Evolus focuses on innovative aesthetic products, particularly Jeuveau®, a neurotoxin exclusively for aesthetics, approved in 2019 by the FDA.
Evolus, Inc. (NASDAQ: EOLS) has secured a $125 million term loan financing with Pharmakon Advisors, L.P. This facility includes an initial draw of $75 million to support corporate purposes and achieve cash flow breakeven. A second $50 million draw is available before December 31, 2022, providing potential for strategic transactions. The loan matures in six years with interest-only payments for the first 39 months. The CEO emphasizes this funding strengthens their capital structure and supports growth in the aesthetic neurotoxin market.
Evolus, Inc. (NASDAQ: EOLS) announced the participation of its management team in two investment conferences this November. The first event is the Stifel 2021 Virtual Healthcare Conference on November 16 at 2:40 pm ET. The second is the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30 at 7:30 am ET. Audio webcasts of both events will be available on Evolus' investor relations website for 90 days following the presentations. Evolus specializes in aesthetic products, including Jeuveau®, the first neurotoxin solely for aesthetics.
Evolus, Inc. reported a record third quarter ending September 30, 2021, with U.S. net revenues reaching $26.7 million, a 58% increase year-over-year. The company's cash position at quarter-end totaled $107.8 million. Key growth drivers included an increase in Jeuveau® customer accounts, rising to over 6,500, and a significant marketing push with over 850 unique campaigns, generating 395 million media impressions. The company also initiated a Phase II clinical program for an “extra strength” Jeuveau® dose aimed at extending duration.
Evolus has initiated a clinical program for an 'extra strength' dose of Jeuveau® (prabotulinumtoxinA-xvfs) aimed at enhancing its aesthetics product line. The company expects to enroll its first patient in Q1 2022, with the study's completion anticipated in the first half of 2023. CEO David Moatazedi states that the strategy aims to provide an expanded offering tailored to consumer performance preferences. This follows the successful approval of the original Jeuveau® in over 31 countries and is supported by a seasoned clinical development team.
Evolus, Inc. (NASDAQ: EOLS) has appointed Jessica Novak as Senior Vice President of Human Resources to enhance its talent management strategy. Novak brings over 20 years of experience from various industries, including consulting and biotech. David Moatazedi, President and CEO, emphasized that her expertise aligns with Evolus' mission to improve the beauty experience. Evolus is known for its aesthetic product, Jeuveau®, which is FDA-approved and aims to innovate within the aesthetics market.
Evolus, Inc. (NASDAQ: EOLS) has announced it will report its Q3 2021 financial results and provide a business update on November 2, 2021, before U.S. market opening. Management will hold a conference call at 9:00 a.m. ET to discuss these results, followed by a Q&A session. Interested parties can participate by calling (877) 407-6184 for U.S. callers or (201) 389-0877 for international callers, or via a live webcast on Evolus' Investor Relations page. A replay of the call will be available post-event.
Evolus, Inc. (NASDAQ: EOLS) announces participation in two investment conferences this September. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand from 7:00am ET. The second is the Cantor 2021 Virtual Global Healthcare Conference on September 28 at 3:20pm ET. Both webcasts will be accessible on Evolus' investor relations website for 90 days post-presentation. Evolus is known for its innovative beauty products, including Jeuveau®, the first neurotoxin dedicated to aesthetics, approved by the FDA in 2019.